AtriCure (NASDAQ:ATRC - Get Free Report) posted its earnings results on Wednesday. The medical device company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.07, Zacks reports. AtriCure had a negative return on equity of 8.12% and a negative net margin of 8.70%. During the same quarter in the previous year, the business earned ($0.21) earnings per share.
AtriCure Stock Performance
Shares of NASDAQ:ATRC traded up $1.35 during trading on Friday, reaching $40.94. The company had a trading volume of 577,628 shares, compared to its average volume of 590,066. The firm has a market capitalization of $2.00 billion, a price-to-earnings ratio of -49.33 and a beta of 1.46. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.62 and a quick ratio of 2.59. The stock's fifty day moving average price is $35.76 and its 200 day moving average price is $31.50. AtriCure has a fifty-two week low of $18.94 and a fifty-two week high of $43.11.
Wall Street Analysts Forecast Growth
ATRC has been the subject of several recent analyst reports. Oppenheimer boosted their target price on AtriCure from $36.00 to $45.00 and gave the stock an "outperform" rating in a research note on Thursday. JMP Securities restated a "market outperform" rating and set a $60.00 target price on shares of AtriCure in a research note on Monday, February 10th. Stifel Nicolaus boosted their target price on AtriCure from $36.00 to $48.00 and gave the stock a "buy" rating in a research note on Thursday. Piper Sandler boosted their price objective on AtriCure from $40.00 to $50.00 and gave the company an "overweight" rating in a research note on Thursday. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $51.00 price objective on shares of AtriCure in a research note on Thursday. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, AtriCure presently has a consensus rating of "Moderate Buy" and an average price target of $51.56.
Get Our Latest Stock Report on ATRC
AtriCure Company Profile
(
Get Free Report)
AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.
See Also
Before you consider AtriCure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AtriCure wasn't on the list.
While AtriCure currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
